Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan

Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%) derived clinical benefit from Trastuzumab deruxtecan (TDXd...

Descripción completa

Detalles Bibliográficos
Autores principales: Alder, Laura, Trapani, Dario, Bradbury, Claire, Van Swearingen, Amanda E. D., Tolaney, Sara M., Khasraw, Mustafa, Anders, Carey K., Lascola, Christopher D., Hsu, Liangge, Lin, Nancy U., Sammons, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063529/
https://www.ncbi.nlm.nih.gov/pubmed/36997605
http://dx.doi.org/10.1038/s41523-023-00519-0
Descripción
Sumario:Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%) derived clinical benefit from Trastuzumab deruxtecan (TDXd), and 4 patients (50%) had an objective partial response based on formal neuroradiology MRI reads using the EORTC/RANO-LM Revised-Scorecard. T-DXd warrants further study in LM in HER2 + MBC and solid tumors where T-DXd may be active.

Ejemplares similares